{"id":224138,"date":"2024-12-26T00:00:00","date_gmt":"2024-12-26T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/47041114-medtech-interventional-cardiology-devices-market\/"},"modified":"2026-03-31T10:10:28","modified_gmt":"2026-03-31T10:10:28","slug":"47042075-medtech-interventional-cardiology-devices-market-insights-japan","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/47042075-medtech-interventional-cardiology-devices-market-insights-japan\/","title":{"rendered":"Interventional Cardiology Devices – Market Insights – Japan"},"content":{"rendered":"

The Japanese IC<\/abbr> device market is intensely competitive and positioned for significant growth, fueled by rising procedure volumes for complex CAD<\/abbr> cases and the adoption of cutting-edge devices and technologies. Strong clinical evidence, particularly for coronary IVL<\/abbr>, will drive market momentum further. Moreover, the introduction of innovative products and advanced diagnostic methods will broaden the eligible patient base. However, market revenues will be offset by eroding ASP<\/abbr>s due to biennial reimbursement cuts by the MHLW<\/abbr>, resulting in overall market contraction over the forecast period.<\/p>\n

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for IC<\/abbr> devices in Japan from 2019 through 2033.<\/p>\n

The coronary stent segment remains intensely competitive, with leading companies continually advancing their flagship devices through innovative updates to maintain their leadership.<\/strong><\/p>\n

What are the market share dynamics among the three major competitors in the highly lucrative DES<\/abbr> device market?<\/p>\n

What competitive strategies are companies using to capture market share in this space, and how are ASP<\/abbr>s being impacted by the strong competition?<\/p>\n

Advancements in technology are transforming the diagnosis and treatment of complex PCI<\/abbr>s.<\/strong><\/p>\n

How will the market landscape for coronary stents evolve over the next few years with the adoption of BRS<\/abbr>?<\/p>\n

What advancements are anticipated in the developmental pipeline for the next generation of BRS<\/abbr>?<\/p>\n

The introduction of intravascular lithotripsy has revolutionized the treatment of calcified coronary lesions and vessel preparation prior to stenting.<\/strong><\/p>\n

How has the commercialization of coronary lithotripsy impacted the use of other products used in the IC device space?<\/p>\n

How is reimbursement changing for coronary lithotripsy, and how will this affect adoption of this technology?<\/p>\n

The growing adoption of alternative coronary physiology modalities is set to reshape the diagnostic market landscape.<\/strong><\/p>\n

What is the impact of the latest generation of alternative coronary physiology modalities, such imaging-based FFR<\/abbr>angio<\/sub> and FFR<\/abbr>CT<\/abbr><\/sub>, on existing intravascular imaging technologies, including traditional FFR<\/abbr> and IVUS<\/abbr>?<\/p>\n

What is the expected impact of emerging balloon-based technologies such as DCB<\/abbr>s?<\/p>\n

How are new clinical trials impacting IC<\/abbr> device segments, procedures, competitors, and products?<\/p>\n

The biennial MHLW<\/abbr> reimbursement cuts are poised to create ongoing headwinds for the Japanese IC<\/abbr> device market, significantly impacting revenue growth, pricing strategies, and market dynamics over time.<\/strong><\/p>\n

\n

Which device market has been most impacted by the MHLW<\/abbr> reimbursement cuts, and how significantly will these cuts affect various device segments?<\/p>\n

What key barriers to entry does MHLW<\/abbr> reimbursement create for new competitors in the Japanese IC<\/abbr> market?<\/p>\n

What strategies are competitors implementing to mitigate the revenue impact of reimbursement cuts?<\/p>\n<\/div>\n","protected":false},"template":"","class_list":["post-224138","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-therapy-area-cardiovascular","medtech-therapy-area-interventional-cardiology-devices","medtech-geography-japan","medtech-date-983"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/224138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":7,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/224138\/revisions"}],"predecessor-version":[{"id":575106,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/224138\/revisions\/575106"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=224138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}